RSS Feed For (NASDAQ:AUXL)

AUXILIUM PHARMACEUT (NASDAQ:AUXL)

30.97 -0 (-0%)
AUXILIUM PHARMACEUT (NASDAQ:AUXL) Delayed :
Previous Close $30.97    52 Week High $37.28 
Open $31.27    52 Week Low $21.85 
Day High $31.40    P/E N/A 
Day Low $30.67    EPS $-1.27 
Volume 950,869       
More AUXL Info: Chart SEC Filings Profile Historical Options

What is this?Friends, Peers and Foes

Ticker # Stories Ticker # Stories
BSTC 4 PFE 3
VPHM 3 VVUS 2
AEM 2 CPHD 2
OC 2 LNC 2
AMLN 2 ARNA 2
MV 1 AVA 1
View All Friends, Peers and Foes

StreetInsider Reports on AUXL by Category

View All Comments Comments on recent AUXL articles

ANDREW OLIVER SATCHELL
on Dec 1, 2009
at 04:13 PM
ANDREW OLIVER SATCHELL GOOD
Article: Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
paul
on Nov 25, 2009
at 03:06 PM
xiaflex xiaflex has a much stronger upward potential than indicated. xiaflex can and will probably be used off label for peyronie's, frozen shoulder, as well as scarring for burn survivors as well as post surgical wounds. Once available to the physician the injectable collagenase will be used by many sub specialties of surgery as well as other specialty groups Auxilium is worth over $50.00 per share, and the supplier of the collagenase, BSTC, is also worth $50.00 per share
Article: Bank of America Resumes Coverage on Auxilium Pharmaceuticals (AUXL) with a Buy
linda butti
on Sep 9, 2009
at 09:41 PM
XIAFLEX(TM)for duentren's I am interested in information on this new treatment
Article: Auxilium Pharmaceuticals (AUXL) XIAFLEX for the Treatment of Dupuytren's Contracture Receives Priority Review From the FDA
paul
on Jun 23, 2009
at 07:24 PM
xiaflex THE OFF LABEL INDICATIONS FOR A COLLAGENASE BASED INJECTIBLE FOR BURN SCARS, POST SURGICAL SCARS, KELOIDS, AS WELL AS OTHER INDICATIONS WOULD GREATLY EXPAND THE USE OF XIAFLEX.
Article: Hapoalim Securities Initiates Coverage on BioSpecifics (BSTC) with a Market Outperform; Possible Acquisition Play
Bob
on Jun 11, 2009
at 03:53 PM
Breen I am interested in knowing when you think this drug will be available to patients. Thanks
Article: Auxilium Pharmaceuticals (AUXL) XIAFLEX for the Treatment of Dupuytren's Contracture Receives Priority Review From the FDA
View All Comments

Comments on AUXL


No comments are currently available.